Aminocaproic Acid Solution
NDC Package 72205-032-71
Package Information
Aminocaproic Acid solution is a medication used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This formulation utilizes a solution delivery system. Marketed by Novadoz Pharmaceuticals Llc, this product is identified by NDC 72205-032 and is authorized under FDA application ANDA215100.
Identification & Billing
- RxCUI: 582299 - aminocaproic acid 0.25 GM/mL Oral Solution
- RxCUI: 582299 - 6-aminocaproic acid 250 MG/ML Oral Solution
- RxCUI: 582299 - 6-aminocaproic acid 0.25 GM per ML Oral Syrup
- RxCUI: 582299 - 6-aminocaproic acid 1.25 GM per 5 ML Oral Syrup
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72205 - Novadoz Pharmaceuticals Llc
- 72205-032 - Aminocaproic Acid
- 72205-032-71 - 236.5 mL in 1 BOTTLE, PLASTIC
- 72205-032 - Aminocaproic Acid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72205-032). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72205-032-71 identifies a specific commercial package of 236.5 ml in 1 bottle, plastic of Aminocaproic Acid, a human prescription drug labeled by Novadoz Pharmaceuticals Llc. This solution is formulated for oral use and contains aminocaproic acid as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novadoz Pharmaceuticals Llc on September 26, 2024. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This may cause serious bleeding after certain surgeries or in certain conditions (such as bleeding disorders, liver disease, cancer). Aminocaproic acid works by helping your blood clot normally. It belongs to a class of drugs known as antifibrinolytics.
How is this Novadoz Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72205003271. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.